中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2015年
10期
509-512
,共4页
杨雪%王靖%张业繁%王翔宇%方仪
楊雪%王靖%張業繁%王翔宇%方儀
양설%왕정%장업번%왕상우%방의
隐匿性乳腺癌%手术%放疗%靶向治疗%预后
隱匿性乳腺癌%手術%放療%靶嚮治療%預後
은닉성유선암%수술%방료%파향치료%예후
occult breast carcinoma%surgery%radiotherapy%target therapy%prognosis
目的:探讨隐匿性乳腺癌的治疗方法和预后。方法:回顾性分析中国医学科学院肿瘤医院1968年1月至2014年6月收治的66例隐匿性乳腺癌患者的临床病理及治疗转归资料。结果:患者中位生存期为75.5(7.0~328.0)个月,仅行腋窝淋巴结清扫的保乳手术与改良根治术者的总生存和无病生存差异无统计学意义(P>0.05)。单因素分析提示腋窝淋巴结分期是唯一可能与无病生存(P=0.035)相关的因素。结论:隐匿性乳腺癌患者保乳术和乳房全切术对于预后无明显影响。腋窝淋巴结转移数目多可能提示预后不良。
目的:探討隱匿性乳腺癌的治療方法和預後。方法:迴顧性分析中國醫學科學院腫瘤醫院1968年1月至2014年6月收治的66例隱匿性乳腺癌患者的臨床病理及治療轉歸資料。結果:患者中位生存期為75.5(7.0~328.0)箇月,僅行腋窩淋巴結清掃的保乳手術與改良根治術者的總生存和無病生存差異無統計學意義(P>0.05)。單因素分析提示腋窩淋巴結分期是唯一可能與無病生存(P=0.035)相關的因素。結論:隱匿性乳腺癌患者保乳術和乳房全切術對于預後無明顯影響。腋窩淋巴結轉移數目多可能提示預後不良。
목적:탐토은닉성유선암적치료방법화예후。방법:회고성분석중국의학과학원종류의원1968년1월지2014년6월수치적66례은닉성유선암환자적림상병리급치료전귀자료。결과:환자중위생존기위75.5(7.0~328.0)개월,부행액와림파결청소적보유수술여개량근치술자적총생존화무병생존차이무통계학의의(P>0.05)。단인소분석제시액와림파결분기시유일가능여무병생존(P=0.035)상관적인소。결론:은닉성유선암환자보유술화유방전절술대우예후무명현영향。액와림파결전이수목다가능제시예후불량。
Objective:Occult breast cancer (OBC) accounts for 0.3%-1.0%of all breast cancers. Because of the rarity of this dis-ease, its treatment and prognosis remain unclear. Our study evaluated the treatment outcomes and prognostic factors associated with OBC. Methods:A total of 82 patients diagnosed with OBC based on available criteria were treated at the Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China, between January 1968 and June 2014. Except for 16 patients who were treated by needle biopsy or excisional biopsy only and were subsequently excluded, all of the cases reported were included in the study. Of the remaining 66 patients, one was male. Patient data, tumor characteristics, and treatment and outcome variables were evaluated. Overall survival (OS) and disease-free survival (DFS) were analyzed. A unicentric retrospective review of 66 patients with OBC was performed. Re-sults:The median follow-up was 75.5 months (7.0-328.0). No significant differences in OS and DFS were observed between patients who underwent mastectomy plus axillary lymph node dissection (Mast+ALND) and those who underwent breast conservation surgery (P>0.05). Univariate analysis revealed that nodal status is a significant prognosis factor of DFS (P=0.031). Conclusion:No significant difference in treatment outcomes between mastectomy+ALND and breast conservation surgery was observed. Nodal status may be an independent predictor of poor outcomes in OBC patients.